Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.

"Declaration of personal interests: Jay Goldstein has served as a speaker, a consultant and/or advisory board member for Amgen, AstraZeneca, Astrellas Pharma US, Horizon, Logical Therapeutics, Merck, Novartis, Pfizer, PLX, Pozen, Proctor Gamble, Tap Pharmaceuticals, Takeda/Sucampo and Wyeth, and has received research funding from Amgen, AstraZeneca, Glaxo Smith Kline, Given, Logical Therapeutics, Novartis, Pfizer, Pozen, Tap Pharmaceuticals and Takeda/Sucampo. Francis Chan has served as a speaker, consultant and/advisory board member for AstraZeneca, Eisai, Pfizer and Takeda. Angel Lanas has served as an advisor for AstraZeneca, Pfizer and Nicox, and has received research funding from AstraZeneca and Pfizer. Charles Wilcox has served as a speaker, a consultant and/or advisory board member for Tap Pharmaceuticals and Salix Pharmaceuticals, and has received research funding from Tap Pharmaceuticals. David Peura has served as a speaker and consultant for Takeda Pharmaceuticals NA, and a consultant for AstraZeneca, Glaxo Smith Kline, Novartis Consumer Health and Pfizer. Jim Scheiman has served as a speaker, a consultant and/or advisory board member for AstraZeneca, Nicox, Novartis, Pfizer, Pozen, Tap Pharmaceuticals and Xlumena, and has received research funding from AstraZeneca. Manuela Berger, George Sands and Ha Nguyen are full-time employees of Pfizer Inc. and all own stocks and shares in Pfizer Inc. Jim Scheiman owns a patent for optical spectroscopy devices through the University of Michigan. Declaration of funding interests: These studies were funded in full by Pfizer Inc. Writing support was provided by L. Prevost, BSc, of PAREXEL, and funded by Pfizer Inc."

"Despite its limitations we believe this study provides important clinical findings. Decreases in haemoglobin are clinically meaningful in that they drive medical evaluations and increased cost of care – the use of the absolute cut-off of ≥2 g/dL has been advocated by the FDA and supported by the European Medicines Agency (EMA), among other researchers."